Literature DB >> 12698094

Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome.

Judith E Worthington1, Susan Martin, Dalia M Al-Husseini, Philip A Dyer, Robert W G Johnson.   

Abstract

BACKGROUND: This study aimed to determine whether the production, in renal transplant recipients, of antibodies directed against donor HLA mismatches is predictive of transplant failure.
METHODS: The failure study group comprised 112 adult recipients of primary renal transplants who had re-entered the transplant waiting list after failure of the first graft. A control group of 123 recipients with functioning transplants was selected from transplantations performed during the same time period, in which patients had equivalent HLA matching and immunosuppression and a minimum of 5 years of follow-up. Sera taken before transplantation and at 1, 3, and 6 months and annually after transplantation were tested by enzyme-linked immunoabsorbent assay (ELISA) for the presence of HLA class I- and class II-specific antibodies. Antibody specificity was defined by a combination of cytotoxicity, ELISA, and flow cytometry techniques to determine whether the antibodies were directed against donor mismatches.
RESULTS: All recipients were negative for donor HLA-specific antibodies before transplantation. After transplantation, 57 (50.9%) of the 112 patients in the failure group produced donor HLA-specific antibodies compared with 2 (1.6%) of the 123 controls (P<0.0001; odds ratio [OR]=64.98; confidence interval [CI], 14.78-399.51). For 60% of the donor-specific antibody-positive patients, antibodies were detected before transplant failure. In 17 cases, these were class I specific; in 14 cases, class II specific; and in 3 cases, specific for both class I and II.
CONCLUSIONS: This study has demonstrated that the production of posttransplantation antibodies directed against donor HLA-A, -B, -Cw, -DR, and -DQ mismatches are all strongly predictive of transplant failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12698094     DOI: 10.1097/01.TP.0000055833.65192.3B

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  40 in total

Review 1.  Immunogenicity and allogenicity: a challenge of stem cell therapy.

Authors:  Dominique Charron; Caroline Suberbielle-Boissel; Reem Al-Daccak
Journal:  J Cardiovasc Transl Res       Date:  2008-09-26       Impact factor: 4.132

2.  Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques.

Authors:  E K Page; A J Page; J Kwun; A C Gibby; F Leopardi; J B Jenkins; E A Strobert; M Song; R A Hennigar; N Iwakoshi; S J Knechtle
Journal:  Am J Transplant       Date:  2012-07-09       Impact factor: 8.086

3.  Binding of anti-HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern.

Authors:  Eduardo Reyes-Vargas; Igor Y Pavlov; Thomas B Martins; Jason J Schwartz; Harry R Hill; Julio C Delgado
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 4.  The link between major histocompatibility complex antibodies and cell proliferation.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Transplant Rev (Orlando)       Date:  2011-07-30       Impact factor: 3.943

Review 5.  The role of complement in antibody-mediated rejection in kidney transplantation.

Authors:  Mark D Stegall; Marcio F Chedid; Lynn D Cornell
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

Review 6.  Treatment options and strategies for antibody mediated rejection after renal transplantation.

Authors:  Matthew H Levine; Peter L Abt
Journal:  Semin Immunol       Date:  2011-09-21       Impact factor: 11.130

Review 7.  Chronic alloantibody mediated rejection.

Authors:  R Neal Smith; Robert B Colvin
Journal:  Semin Immunol       Date:  2011-11-02       Impact factor: 11.130

Review 8.  Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling.

Authors:  Thangamani Muthukumar; John R Lee; Darshana M Dadhania; Ruchuang Ding; Vijay K Sharma; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplant Rev (Orlando)       Date:  2014-05-27       Impact factor: 3.943

9.  Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program.

Authors:  Hamid Khan; Muhammed Mubarak; Tahir Aziz; Ejaz Ahmed; Syed Fazal Akhter; Javed Kazi; Syed Aa Naqvi; Syed Ah Rizvi
Journal:  J Nephropathol       Date:  2014-04-01

10.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.